{
  "abstract": "Background\n\nVentricular arrhythmia (VA) substantially contributes to sudden cardiac death in patients with acute myocardial infarction (AMI) and type 2 diabetes mellitus (T2DM). Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have demonstrated cardiovascular benefits; however, their influence on post-AMI ventricular arrhythmogenesis remains unclear.Methods\n\nThis retrospective cohort study included 1,873 patients with concurrent AMI and T2DM admitted between January 2018 and December 2022. Using propensity score matching (1:2, nearest-neighbor), 277 GLP-1RA users were matched with 554 controls. The primary endpoint was incident VA. Cox proportional hazards regression, inverse probability of treatment weighting (IPTW), Firth's penalized likelihood regression, and Fine-Gray competing risk analysis were performed.Results\n\nOver a median follow-up of 2.5 years, GLP-1RA use was associated with a reduced risk of VA (adjusted HR 0.61, 95% CI 0.37-0.98, P = 0.040), MACE (HR 0.66, 95% CI 0.45-0.96, P = 0.030), cardiovascular death (HR 0.52, 95% CI 0.32-0.86, P = 0.010), and heart failure rehospitalization (HR 0.42, 95% CI 0.26-0.68, P < 0.001). All-cause mortality showed a non-significant trend (HR 0.84, 95% CI 0.59-1.18, P = 0.310). Firth's penalized regression confirmed the primary finding (HR 0.58, 95% CI 0.36-0.95, P = 0.029). The Fine-Gray model yielded a subdistribution HR of 0.63 (95% CI 0.39-1.02, P = 0.058) after accounting for competing mortality risk. The 90-day landmark analysis (HR 0.65, 95% CI 0.39-1.06, P = 0.085) and the time-varying exposure Cox model (HR 0.66, 95% CI 0.40-1.08, P = 0.097) were directionally concordant but did not reach statistical significance.Conclusions\n\nGLP-1RA therapy was associated with a lower risk of VA and improved cardiovascular outcomes in patients with AMI and T2DM. Because several sensitivity analyses, including the Fine-Gray competing-risk, landmark, and time-varying models, were borderline non-significant, these findings should be interpreted with caution and regarded as hypothesis-generating, warranting confirmation in prospective randomized trials.",
  "abstract_shown": true,
  "affiliations": [
    "Department of Cardiology, 920th Hospital of the Joint Logistics Support Force, Kunming City, Yunnan, 650032, China.",
    "Department of Cardiovascular Medicine, Hospital No. 922, Joint Logistics Support Force, Hengyang City, Hunan, 421200, China.",
    "Department of Cardiology, 920th and 922nd Hospital of Joint Logistics Support Force, PLA, No. 212, Daguan Road, Kunming, Yunnan, 650032, China. ruiwei19373491717@126.com."
  ],
  "article_type": "research article",
  "arxiv": null,
  "author_total": 6,
  "authors": [
    {
      "affs": [
        0
      ],
      "name": "Chunqin Hu"
    },
    {
      "affs": [
        0
      ],
      "name": "Wenming Zhao"
    },
    {
      "affs": [
        1
      ],
      "name": "Shasha Xiao"
    },
    {
      "affs": [
        1
      ],
      "name": "Jiujiu Shi"
    },
    {
      "affs": [
        1
      ],
      "name": "Wenhua Liang"
    },
    {
      "affs": [
        2
      ],
      "name": "Ruiwei Guo"
    }
  ],
  "bibtex": "https://research.draconitic.com/paper/f35t8p46wfwx5.bib",
  "cited_by": 0,
  "doi": "10.1186/s12872-026-06354-y",
  "fulltext_url": "https://europepmc.org/articles/PMC13721462",
  "id": "f35t8p46wfwx5",
  "issns": [
    "1471-2261"
  ],
  "landing_url": "https://europepmc.org/article/MED/42958020",
  "language": "eng",
  "licence": "CC-BY-NC-ND",
  "licence_label": "CC BY-NC-ND",
  "licence_source": "article",
  "licence_url": "https://creativecommons.org/licenses/by-nc-nd/4.0/",
  "metadata_licence": null,
  "native_subjects": [
    [
      "heading",
      "Research"
    ],
    [
      "openalex",
      "2712|Diabetes Treatment and Management"
    ]
  ],
  "openalex": "W7172277573",
  "pdf_url": "https://europepmc.org/articles/PMC13721462?pdf=render",
  "pmcid": "PMC13721462",
  "pmid": "42958020",
  "published": "2026-08-03",
  "publisher": "BMC",
  "ris": "https://research.draconitic.com/paper/f35t8p46wfwx5.ris",
  "sources": [
    {
      "first_seen": "2026-11-01T00:20:47Z",
      "native_id": "MED:42958020",
      "source": "europepmc",
      "url": "https://europepmc.org/article/MED/42958020"
    },
    {
      "first_seen": "2026-11-03T12:22:09Z",
      "native_id": "PMC13721462",
      "source": "pmc",
      "url": "https://doi.org/10.1186/s12872-026-06354-y"
    }
  ],
  "subjects": [
    {
      "field": "medicine",
      "origin": "openalex:2712|Diabetes Treatment and Management",
      "subfield": "endocrinology-metabolism"
    }
  ],
  "title": "Glucagon-like peptide-1 receptor agonists and the risk of ventricular arrhythmia in patients with acute myocardial infarction and type 2 diabetes mellitus: a propensity score-matched cohort study.",
  "title_text": "Glucagon-like peptide-1 receptor agonists and the risk of ventricular arrhythmia in patients with acute myocardial infarction and type 2 diabetes mellitus: a propensity score-matched cohort study.",
  "type": "peer-reviewed",
  "updated_at": "2026-11-03T12:22:09Z",
  "url": "https://research.draconitic.com/paper/f35t8p46wfwx5",
  "venue": "BMC cardiovascular disorders",
  "versions": []
}